1)Gass JD, Blodi BA:Idiopathic juxtafoveolar retinal telangiectasis. Update of classification and follow-up study. Ophthalmology 100:1536-1546, 1993
2)Yannuzzi LA, Bardal AM, Freund KB et al:Idiopathic macular telangiectasia. Arch Ophthalmol 124:450-460, 2006
3)Ooto S, Hangai M, Takayama K et al:High-resolution photoreceptor imaging in idiopathic macular telangiectasia type 2 using adaptive optics scanning laser ophthalmoscopy. Invest Ophthalmol Vis Sci 52:5541-5550, 2011
4)Ooto S, Hangai M, Takayama K et al:Comparison of cone pathologic changes in idiopathic macular telangiectasia types 1 and 2 using adaptive optics scanning laser ophthalmoscopy. Am J Ophthalmol 155:1045-1057, 2013
5)Hirano Y, Yasukawa T, Usui Y et al:Indocyanine green angiography-guided laser photocoagulation combined with sub-Tenon's capsule injection of triamcinolone acetonide for idiopathic macular telangiectasia. Br J Ophthalmol 94:600-605, 2010
6)Takayama K, Ooto S, Tamura H et al:Intravitreal bevacizumab for type 1 idiopathic macular telangiectasia. Eye(Lond) 24:1492-1497, 2010
7)Moon BG, Kim YJ, Yoon YH et al:Use of intravitreal bevacizumab injections to treat type 1 idiopathic macular telangiectasia. Graefes Arch Clin Exp Ophthalmol 250:1697-1699, 2012
8)Charbel Issa P, Finger RP, Kruse K et al:Monthly ranibizumab for nonproliferative macular telangiectasia type 2:a 12-month prospective study. Am J Ophthalmol 151:876-886, 2011
9)Chew EY, Clemons TE, Peto T et al:MacTel-CNTF Research Group. Ciliary neurotrophic factor for macular telangiectasia type 2:results from a phase 1 safety trial. Am J Ophthalmol 159:659-666, 2015
10)Karth PA, Raja SC, Brown DM et al:Outcomes of macular hole surgeries for macular telangiectasia type 2. Retina 34:907-915, 2014